Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer ; volume:13 ; number:1 ; day:11 ; month:11 ; year:2023 ; pages:1-11 ; date:12.2023
Scientific reports ; 13, Heft 1 (11.11.2023), 1-11, 12.2023
- Creator
-
Shikata, Shohei
Murata, Takeshi
Yoshida, Masayuki
Hashiguchi, Hiromi
Yoshii, Yukiko
Ogawa, Ayumi
Watase, Chikashi
Shiino, Sho
Sugino, Hirokazu
Jimbo, Kenjiro
Maeshima, Akiko
Iwamoto, Eriko
Takayama, Shin
Suto, Akihiko
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-023-47033-8
- URN
-
urn:nbn:de:101:1-2024013013082062749802
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 8:09 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Shikata, Shohei
- Murata, Takeshi
- Yoshida, Masayuki
- Hashiguchi, Hiromi
- Yoshii, Yukiko
- Ogawa, Ayumi
- Watase, Chikashi
- Shiino, Sho
- Sugino, Hirokazu
- Jimbo, Kenjiro
- Maeshima, Akiko
- Iwamoto, Eriko
- Takayama, Shin
- Suto, Akihiko
- SpringerLink (Online service)
Other Objects (12)
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
Image analysis-based identification of high risk ER-positive, HER2-negative breast cancers
Budget Impact of the Oncotype DX Breast Recurrence Score ® Test in Patients with Early Primary Hormone-Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in Germany
Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
Image analysis-based identification of high risk ER-positive, HER2-negative breast cancers
Budget Impact of the Oncotype DX Breast Recurrence Score ® Test in Patients with Early Primary Hormone-Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in Germany
Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
Image analysis-based identification of high risk ER-positive, HER2-negative breast cancers
Budget Impact of the Oncotype DX Breast Recurrence Score ® Test in Patients with Early Primary Hormone-Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in Germany
Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified